Group | Chi-Square Tests(p-value) | t-test(p-value) | |||||
---|---|---|---|---|---|---|---|
TACE + Sunitinib group(N = 47) | Sunitinib group(N = 51) | Pearson Chi-Square | Fisher’s Exact Test | ||||
Post-Treatment ECOG | 0 | Count(%) | 11(23.4%) | 11(21.6%) | 0.570 | ||
1 | Count(%) | 24(51.1%) | 22(43.1%) | ||||
2 | Count(%) | 12(25.5%) | 18(35.3%) | ||||
Post-treatment liver function | Child A | Count(%) | 32(68.1%) | 33(64.7%) | 0.831 | ||
Child B | Count(%) | 15(31.9%) | 18(35.3%) | ||||
Post-treatment bilirubin(µmol/L) | Mean ± SD | 16.1 ± 4.8 | 15.0 ± 5.3 | 0.306 | |||
Post-treatment Albumin(g/L) | Mean ± SD | 35.76 ± 5.41 | 33.37 ± 3.05 | 0.008 | |||
Post-treatment BUN(mmol/L) | Mean ± SD | 7.71 ± 0.89 | 7.54 ± 0.98 | 0.347 | |||
Post-Treatment Cr(µmol/L) | Mean ± SD | 110.3 ± 20.8 | 105.0 ± 25.6 | 0.269 | |||
Post-Treatment GFR(ml/min) | Mean ± SD | 95.78 ± 12.97 | 99.34 ± 12.46 | 0.168 | |||
Post-Treatment WBC(G/L) | Mean ± SD | 6.92 ± 0.72 | 3.52 ± 0.73 | < 0.001 | |||
Post-Treatment RBC(T/L) | Mean ± SD | 3.64 ± 0.66 | 3.37 ± 0.74 | 0.062 | |||
Post-Treatment PLT(G/L) | Mean ± SD | 95.40 ± 18.03 | 87.90 ± 23.32 | 0.080 |